TN2009000151A1 - Mapk/erk kinase inhibitors - Google Patents

Mapk/erk kinase inhibitors

Info

Publication number: TN2009000151A1
Authority: TN; Tunisia
Prior art keywords: mapk; kinase inhibitors; erk kinase; erk; mek
Prior art date: 2006-10-23

Application number

TNP2009000151A

Other languages

English (en)

Inventor

Qing Dong

Victoria Feher

Stephen W Kaldor

Naoki Tomita

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-23

Filing date

2009-04-22

Publication date

2010-10-18

2009-04-22 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2010-10-18 Publication of TN2009000151A1 publication Critical patent/TN2009000151A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

TNP2009000151A 2006-10-23 2009-04-22 Mapk/erk kinase inhibitors TN2009000151A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US86256906P	2006-10-23	2006-10-23
PCT/US2007/082138 WO2008140553A2 (fr)	2006-10-23	2007-10-22	Inhibiteurs de la kinase mapk/erk

Publications (1)

Publication Number	Publication Date
TN2009000151A1 true TN2009000151A1 (en)	2010-10-18

Family

ID=39954277

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000151A TN2009000151A1 (en)	2006-10-23	2009-04-22	Mapk/erk kinase inhibitors

Country Status (25)

Country	Link
US (4)	US7696218B2 (fr)
EP (1)	EP2091941B1 (fr)
JP (1)	JP5249939B2 (fr)
KR (1)	KR20090071666A (fr)
CN (1)	CN101563338A (fr)
AR (1)	AR063357A1 (fr)
AU (1)	AU2007353385A1 (fr)
BR (1)	BRPI0717374A2 (fr)
CA (1)	CA2667447A1 (fr)
CL (1)	CL2007003041A1 (fr)
CO (1)	CO6180442A2 (fr)
CR (1)	CR10818A (fr)
DO (1)	DOP2009000089A (fr)
EA (1)	EA200970407A1 (fr)
EC (1)	ECSP099354A (fr)
IL (1)	IL198254A0 (fr)
MA (1)	MA30889B1 (fr)
MX (1)	MX2009004269A (fr)
NO (1)	NO20091999L (fr)
NZ (1)	NZ577047A (fr)
PE (1)	PE20081468A1 (fr)
TN (1)	TN2009000151A1 (fr)
TW (1)	TW200831100A (fr)
WO (1)	WO2008140553A2 (fr)
ZA (1)	ZA200903274B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2007353385A1 (en) *	2006-10-23	2008-11-20	Takeda Pharmaceutical Company Limited	MAPK/ERK kinase inhibitors
JO2985B1 (ar) *	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	مثبطات كينازmapk/erk
ES2456966T3 (es)	2007-11-12	2014-04-24	Takeda Pharmaceutical Company Limited	Inhibidores de MAPK/ERK cinasa
ES2616231T3 (es) *	2008-08-21	2017-06-12	Immunogenics Llc	Formulación para administración oral de proteínas
US9199946B2 (en) *	2012-04-03	2015-12-01	Bristol-Myers Squibb Company	Pyrimidinone carboxamide inhibitors of endothelial lipase
CA2900012A1 (fr)	2013-02-08	2014-08-14	Celgene Avilomics Research, Inc.	Inhibiteurs d'erk et leurs utilisations
US10005760B2 (en)	2014-08-13	2018-06-26	Celgene Car Llc	Forms and compositions of an ERK inhibitor
DE102015117207A1 (de)	2015-10-08	2017-04-13	Silas Mehmet Aslan	Verfahren zur Herstellung von polythiophenhaltigen Fluiden
IL259810A (en)	2018-06-04	2018-07-31	Yeda Res & Dev	Mitogen-activated protein kinase kinase 7 inhibitors
GB202202297D0 (en)	2022-02-21	2022-04-06	Verona Pharma Plc	Formulation production process
TW202506117A (zh)	2023-06-26	2025-02-16	英商維羅納製藥Ｐｌｃ公司	顆粒組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS58152890A (ja) *	1982-03-08	1983-09-10	Takeda Chem Ind Ltd	イソキサゾロピリミジン誘導体
AU5610398A (en)	1997-02-28	1998-09-18	Warner-Lambert Company	Method of treating or preventing septic shock by administering a mek inhibitor
ES2229515T3 (es)	1997-07-01	2005-04-16	Warner-Lambert Company Llc	Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek.
CA2290509A1 (fr)	1997-07-01	1999-01-14	Warner-Lambert Company	Derives d'acide benzoique 2-(4-bromo ou 4-iodo phenylamino) et utilisation de ces derniers en tant qu'inhibiteurs de mek
AU2483400A (en)	1999-01-13	2000-08-01	Warner-Lambert Company	4'heteroaryl diarylamines
WO2000075118A1 (fr)	1999-06-03	2000-12-14	Vertex Pharmaceuticals Incorporated	INHIBITEURS DE KINASES c-JUN N-TERMINALES (JNK)
CN1219753C (zh)	2000-07-19	2005-09-21	沃尼尔·朗伯公司	4－碘苯氨基苯氧肟酸的氧合酯
WO2005000818A1 (fr) *	2003-06-27	2005-01-06	Warner-Lambert Company Llc	Derives de 4-[phenylamino (substitue)]-2-pyridone a substitution en 5 en tant qu'inhibiteurs de la mek
US7538120B2 (en) *	2003-09-03	2009-05-26	Array Biopharma Inc.	Method of treating inflammatory diseases
WO2005051300A2 (fr)	2003-11-19	2005-06-09	Array Biopharma Inc.	Inhibiteurs bicycliques de mek et leurs procedes de production
EP1838675A1 (fr)	2004-11-24	2007-10-03	Laboratoires Serono S.A.	Nouveaux dérivés de 4-arylaminopyridone en tant qu'inhibiteurs de mek pour le traitement des troubles hyperproliferatifs
US20060223807A1 (en) *	2005-03-29	2006-10-05	University Of Massachusetts Medical School, A Massachusetts Corporation	Therapeutic methods for type I diabetes
EP1967516B1 (fr)	2005-05-18	2009-11-04	Array Biopharma, Inc.	Derivés 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide en tant que inhibiteurs MEK pour le traitement de maladies hyperproliferatives
AU2007353385A1 (en) *	2006-10-23	2008-11-20	Takeda Pharmaceutical Company Limited	MAPK/ERK kinase inhibitors
JO2985B1 (ar)	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	مثبطات كينازmapk/erk
ES2456966T3 (es)	2007-11-12	2014-04-24	Takeda Pharmaceutical Company Limited	Inhibidores de MAPK/ERK cinasa
US20090246198A1 (en) *	2008-03-31	2009-10-01	Takeda Pharmaceutical Company Limited	Mapk/erk kinase inhibitors and methods of use thereof

2007
- 2007-10-22 AU AU2007353385A patent/AU2007353385A1/en not_active Abandoned
- 2007-10-22 JP JP2009534802A patent/JP5249939B2/ja active Active
- 2007-10-22 WO PCT/US2007/082138 patent/WO2008140553A2/fr not_active Ceased
- 2007-10-22 NZ NZ577047A patent/NZ577047A/en not_active IP Right Cessation
- 2007-10-22 US US11/876,635 patent/US7696218B2/en active Active
- 2007-10-22 EP EP07874225A patent/EP2091941B1/fr active Active
- 2007-10-22 US US12/446,974 patent/US20100204471A1/en not_active Abandoned
- 2007-10-22 ZA ZA200903274A patent/ZA200903274B/xx unknown
- 2007-10-22 EA EA200970407A patent/EA200970407A1/ru unknown
- 2007-10-22 MX MX2009004269A patent/MX2009004269A/es active IP Right Grant
- 2007-10-22 KR KR1020097010570A patent/KR20090071666A/ko not_active Withdrawn
- 2007-10-22 CA CA002667447A patent/CA2667447A1/fr not_active Abandoned
- 2007-10-22 BR BRPI0717374-1A patent/BRPI0717374A2/pt not_active IP Right Cessation
- 2007-10-22 CN CNA2007800471578A patent/CN101563338A/zh active Pending
- 2007-10-23 CL CL200703041A patent/CL2007003041A1/es unknown
- 2007-10-23 TW TW096139723A patent/TW200831100A/zh unknown
- 2007-10-23 AR ARP070104689A patent/AR063357A1/es not_active Application Discontinuation
- 2007-10-23 PE PE2007001430A patent/PE20081468A1/es not_active Application Discontinuation
2009
- 2009-04-21 IL IL198254A patent/IL198254A0/en unknown
- 2009-04-22 TN TNP2009000151A patent/TN2009000151A1/fr unknown
- 2009-04-23 DO DO2009000089A patent/DOP2009000089A/es unknown
- 2009-05-13 MA MA31870A patent/MA30889B1/fr unknown
- 2009-05-21 EC EC2009009354A patent/ECSP099354A/es unknown
- 2009-05-21 CR CR10818A patent/CR10818A/es not_active Application Discontinuation
- 2009-05-22 NO NO20091999A patent/NO20091999L/no not_active Application Discontinuation
- 2009-05-22 CO CO09053035A patent/CO6180442A2/es not_active Application Discontinuation
2010
- 2010-01-05 US US12/652,570 patent/US7943626B2/en active Active
2011
- 2011-04-07 US US13/082,259 patent/US8088783B2/en active Active

Also Published As

Publication number	Publication date
ECSP099354A (es)	2009-06-30
AU2007353385A1 (en)	2008-11-20
MX2009004269A (es)	2009-08-12
DOP2009000089A (es)	2010-03-31
EP2091941B1 (fr)	2013-01-23
NZ577047A (en)	2011-02-25
US20100113413A1 (en)	2010-05-06
MA30889B1 (fr)	2009-11-02
WO2008140553A2 (fr)	2008-11-20
JP2010507683A (ja)	2010-03-11
EA200970407A1 (ru)	2009-12-30
AR063357A1 (es)	2009-01-21
BRPI0717374A2 (pt)	2013-10-29
CO6180442A2 (es)	2010-07-19
EP2091941A2 (fr)	2009-08-26
US8088783B2 (en)	2012-01-03
NO20091999L (no)	2009-07-06
PE20081468A1 (es)	2008-12-03
JP5249939B2 (ja)	2013-07-31
WO2008140553A3 (fr)	2009-02-26
CN101563338A (zh)	2009-10-21
US7696218B2 (en)	2010-04-13
US20100204471A1 (en)	2010-08-12
TW200831100A (en)	2008-08-01
CR10818A (es)	2009-07-07
US20110190261A1 (en)	2011-08-04
US7943626B2 (en)	2011-05-17
CL2007003041A1 (es)	2008-03-24
KR20090071666A (ko)	2009-07-01
US20080125437A1 (en)	2008-05-29
ZA200903274B (en)	2010-08-25
CA2667447A1 (fr)	2008-11-20
WO2008140553A4 (fr)	2009-04-30
IL198254A0 (en)	2009-12-24

Publication	Publication Date	Title
WO2008055236A3 (fr)	2008-10-09	Inhibiteurs de kinase mapk/erk
TN2009000151A1 (en)	2010-10-18	Mapk/erk kinase inhibitors
MY146989A (en)	2012-10-15	Kinase inhibitors
ATE479687T1 (de)	2010-09-15	Kinaseinhibitoren
TN2009000249A1 (en)	2010-10-18	Mapk/erk kinase inhibitors
WO2008115890A3 (fr)	2009-04-30	Inhibiteurs de mapk/erk kinase
WO2009146034A3 (fr)	2010-07-15	Inhibiteurs de kinases mapk/erk et procédés d’utilisation de ceux-ci
WO2007028135A3 (fr)	2007-11-01	Composes a base d'imidazopyridine
WO2006105127A3 (fr)	2007-03-22	Inhibiteurs de l'hydroxysteroide deshydrogenase
WO2007075847A3 (fr)	2007-10-04	Activateurs de glucokinase
WO2007061923A3 (fr)	2007-11-01	Activateurs de la glucokinase
WO2007117995A3 (fr)	2008-01-10	Inhibiteurs de kinase
WO2006066109A3 (fr)	2009-04-23	Inhibiteurs des hydroxysteroides deshydrogenases
WO2011113798A3 (fr)	2011-11-17	Nouveaux composés d'inhibiteurs enzymatiques
TN2010000131A1 (en)	2011-09-26	Polo-like kinase inhibitors
WO2007084390A3 (fr)	2007-09-20	Inhibiteurs des histone desacetylases
TN2011000207A1 (en)	2012-12-17	Akt and p70 s6 kinase inhibitors
WO2006122319A3 (fr)	2007-11-15	Inhibiteurs d'histone deacetylase
WO2008054956A3 (fr)	2008-09-04	Inhibiteurs de kinases
WO2008045834A3 (fr)	2008-07-24	Inhibiteurs de kinases
WO2009129401A8 (fr)	2009-12-17	Inhibiteurs de kinases
WO2007148102A3 (fr)	2008-03-13	Hydrochlorure crystallin de duloxétine
MX2008009830A (es)	2009-05-11	Efecto del inhibidor bst2.
WO2008089005A3 (fr)	2009-01-15	Inhibiteurs de rénine
MX2009003793A (es)	2009-12-14	Inhibidores de cinasa.